Danaher (DHR)
(Delayed Data from NYSE)
$264.71 USD
+0.22 (0.08%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $263.65 -1.06 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$264.71 USD
+0.22 (0.08%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $263.65 -1.06 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Danaher (DHR) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Danaher's (DHR) Q1 results are expected to reflect healthy segmental growth. However, adverse impacts of the coronavirus outbreak on demand are anticipated to have ailed.
Timing the Market, Is it Possible? - May 04, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Danaher (DHR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Danaher (DHR) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
General Electric (GE) Q1 Earnings Lag Estimates, View Gloomy
by Zacks Equity Research
General Electric's (GE) first-quarter 2020 earnings reflect the adverse impacts of the coronavirus outbreak. Persistence of the headwinds is likely to impact second-quarter results as well.
The Coronavirus Impact on Corporate Earnings
by Sheraz Mian
We discuss today the Covid-19 impact on corporate earnings, in addition to featuring new research reports on AP (SAP), NIKE (NKE) and others.
Healthy Business to Aid Danaher in Q1 Despite Coronavirus Woes
by Zacks Equity Research
Danaher's (DHR) healthy businesses are likely to aid, driven by segmental performances in the first quarter of 2020. However, concerns related to the coronavirus outbreak persist.
When Does Market Timing Actually Work? - April 14, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
General Electric Take Multiple Debt Restructuring Actions
by Zacks Equity Research
General Electric (GE) commences multiple actions to strengthen its financial positions. Proceeds from the BioPharma divestment and new debt offerings have been used for reducing leverage.
Danaher Gives Update on Q1 Results, Withdraws 2020 Guidance
by Zacks Equity Research
Danaher (DHR) provides an update on first-quarter 2020 results and withdraws its earlier announced guidance for 2020 on the impacts of the coronavirus outbreak.
General Electric Withdraws 2020 View on Coronavirus Concerns
by Zacks Equity Research
General Electric (GE) suspends 2020 projections on uncertainties related to the coronavirus outbreak. Also, earnings in the first quarter are expected to be weaker than previously expected.
Analysts Estimate Danaher (DHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher (DHR) Prices Senior Notes Offering Worth Euro 750M
by Zacks Equity Research
Danaher (DHR) prices euro 750 million worth of senior notes offerings. The net proceeds will be used for satisfying generate corporate purposes, including repaying debts.
Danaher Closes Buyout of General Electric's BioPharma Business
by Zacks Equity Research
Danaher (DHR) completes the acquisition of General Electric's BioPharma business. The buyout will likely strengthen the company's biologics workflow solutions business.
General Electric Closes Divestment of BioPharma to Danaher
by Zacks Equity Research
General Electric (GE) completes the divestment of its BioPharma business to Danaher. The net proceeds received from the transaction will be used by General Electric to lower its debt burden.
Top Stock Reports for Stryker, Shopify & Activision Blizzard
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Stryker (SYK), Shopify (SHOP) and Activision Blizzard (ATVI).
Danaher (DHR) Prices Euro 1.75B Worth Senior Notes Offering
by Zacks Equity Research
Danaher (DHR) prices euro 1.75 billion worth of senior notes offerings. The net proceeds will be used for satisfying generate corporate purposes, including repaying debts.
Conglomerates Accelerate Efforts to Fight Coronavirus Menace
by Avisekh Bhattacharjee
Several industrial conglomerates including General Electric (GE), Honeywell (HON), Danaher (DHR) and 3M (MMM) are increasing steps to mitigate the effects of the coronavirus menace.
General Electric Announces Coronavirus' Impacts on Its Business
by Zacks Equity Research
General Electric's (GE) aviation segment seeks to lower the U.S. workforce by 10% on coronavirus concerns. The company announces various other measures to deal with the impact of the outbreak.
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
Top Stock Reports for Visa, Bank of America & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Bank of America (BAC) and Citigroup (C).
Coronavirus Test Kit Demand to Drive These 3 Stocks
by Zacks Equity Research
Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
Danaher to Soon Close BioPharma Buyout, Receives FTC Approval
by Zacks Equity Research
Danaher (DHR) receives a go-ahead for the acquisition of GE's BioPharma business. The buyout will likely strengthen its biologics workflow solutions business.
Yes, You Can Time the Market. Find out How - March 20, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Align Technology to Acquire exocad in Digital Dentistry Space
by Zacks Equity Research
This acquisition is expected to boost Align Technology's (ALGN) portfolio of Invisalign and iTero digital solutions.